Publications by authors named "Inmaculada Guasch"

Claim this Profile
V
VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02).
Jaime Feliu, Rocio Garcia-Carbonero, Jaume Capdevila, Inmaculada Guasch, Vicente Alonso-Orduna

Cancer Med· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors.
Manuel Benavides, Carles Pericay, Manuel Valladares-Ayerbes, Silvia Gil-Calle, Bartomeu Massutí, Inmaculada Guasch

Clin Colorectal Cancer· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
Miguel Nogué, Antonieta Salud, Pilar Vicente, Antonio Arriví, José María Roca, Inmaculada Guasch

Oncologist· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of irinotecan (CPT-11) administered every 2 weeks as treatment for patients with colorectal cancer resistant to previous treatment with 5-fluorouracil-based therapies: comparison of two different dose schedules (250 and 200 mg/m2) according to toxicity prognostic factors.
Eugeni Saigi, Antonieta Salut, Juan Manuel Campos, Ferran Losa, Hermini Manzano, Inmaculada Guasch

Anticancer Drugs· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis